Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects

NCT05833906 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: CKR-051 Dose 1
DRUG: CKR-051 Dose 2
DRUG: CKR-051 Dose 3
DRUG: CKR-051 Dose 4
DRUG: Placebo

Sponsor

CK Regeon Inc.